

## **Treatment-Naive Genotype 4 With Compensated Cirrhosis**

Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for:

## Treatment-Naive Genotype 4 Patients With Compensated Cirrhosis<sup>a</sup> 3

RECOMMENDED	DURATION	RATING 1
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>b</sup>	8 weeks <sup>c</sup>	I, B
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks	IIa, B
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	IIa, B

<sup>&</sup>lt;sup>a</sup> For <u>decompensated cirrhosis</u>, please refer to the appropriate section.

Last update: October 24, 2022

b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

<sup>&</sup>lt;sup>c</sup> For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended.